Wednesday, November 18, 2026
Late edition · Updated as it breaks
Log inSubmit a story

“All the news worth catching.”

PaparazziPaparazzi
How to earnPaparazzi InkBack PageHolder perksLeaderboardAssignmentsContestsLeagueCity
Catcher tip lineCaught a story first? Earn stock tokens →
Sponsored
Premium projects
DEDeFadePAPackedYour project here
PaparazziPaparazzi

All the news worth catching.

Breaking news on tech, crypto, EVs, e-commerce and social the moment it breaks. Written by AI from verified reporting.

SectionsTop storiesRobinhood ChainTech & AIE-commerceWeb3 & CryptoEV & EnergyGlobal & SocialEntertainmentGamingSportsBusiness & marketsHealth & sciencePolitics & world
EarnStart hereSubmit a storyHow to earnLeaderboardContestsCatcher desksTop catchers by reputationAssignmentsCity LeagueNews bountiesCityMy catchesRewards
MarketsLive statsProof of payoutsWhale watchDeep Scan token checksStock fundToken utilityRobinhood Chain launchesRobinhood Chain projectsPremium project pagesPartnersThe Chain Weekly
PaparazziPaparazzi InkPaparazzi Ink top writersThe Back PageSuggest a Back Page storyPaparazzi on TelegramHow it worksFAQProof of workAbout usHow we score trustEditorial policyPrivacy policyCorrectionsRelease notesAdvertiseContact
$PAPA contract · Robinhood Chain
© 2026 Paparazzi

Written by AI from verified reporting. Not financial advice.

  • Home
  • Submit
  • Earn
  • Sign in
Top storiesRobinhood ChainTech & AIE-commerceWeb3 & CryptoEV & EnergyGlobal & SocialEntertainmentGamingSportsBusiness & marketsHealth & sciencePolitics & worldWhales
Health & science
Important· 61

Viagra-Style Pill Slows Alzheimer's Decline by 31% in Global Trial

A stage three trial across 13 countries found AR1001, a pill from the same drug family as Viagra, slowed cognitive decline by 31% in early Alzheimer's patients taking no other treatment. South Korean maker AriBio reported the results in Boston, though the benefit faded in patients already on other Alzheimer's drugs.

By the Paparazzi desk Caught by @Crypto fresh
Early Catcher
November 18, 2026 · 5:00 AM · theguardian.com · 1 view
Fact boxTrust 65/100 · Developing
What we verified
  • Original source: theguardian.com.
  • The source published it on Nov 18, 2026 at 5:00 AM.
What we couldn't
  • No second outlet has reported it yet. Treat it as a single-source claim.

A pill that works like Viagra on the brain's blood supply cut cognitive decline by 31% in people with early Alzheimer's disease who were taking no other treatment. South Korean drugmaker AriBio presented the stage three trial results at the Clinical Trials on Alzheimer's Disease conference in Boston, covering patients across 13 countries including the UK.

The drug, AR1001, is a phosphodiesterase-5 inhibitor, the same family of medicines as Viagra. AriBio said the decline slowed in 604 people who took AR1001 alone. In a broader group also taking other Alzheimer's drugs, the tablet failed to hit statistically significant results.

Sponsored

Prof Tara Spires-Jones of the University of Edinburgh called the results 'very promising', noting the drug boosts blood flow and likely stimulates brain pathways tied to learning and memory. Dr Sheona Scales of Alzheimer's Research UK said the findings marked 'an important milestone', and that AR1001 was 'especially interesting' because it acts on a specific enzyme rather than targeting amyloid like existing treatments.

Dr Richard Oakley of the Alzheimer's Society said the topline results were 'an exciting sign' of a possible 'totally new treatment' that tackles causes rather than symptoms, and highlighted its once-a-day tablet form as a simpler option. He flagged that the drug appeared less effective for people already on other Alzheimer's medications, something he said needs more study.

Oakley also drew a clear line on the Viagra comparison: AR1001 is being developed specifically for Alzheimer's, and people should not take Viagra to try to treat the disease. All the experts said further trials are needed, and the drug must clear scientific scrutiny and drug regulators before it can be prescribed.

There is still no cure for Alzheimer's, the most common form of dementia, which is forecast to affect 153 million people worldwide by 2050.

TopicsAriBio · AR1001 · Viagra · Tara Spires-Jones · Sheona Scales · Richard Oakley · Alzheimer's Research UK · Alzheimer's Society

Share

Source: theguardian.com

Written by AI from verified reporting.

More stories

  • Health & science 51 minutes ago · theguardian.com · 1 view
    NHS staff snooped on patients' records 3,029 times in five years
  • Health & science 1 hour ago · casrai.org · 1 view
    FDA Opens Its Review Files to Foreign Regulators, Starting With PEPFAR Drugs
  • Health & science 5 hours ago · medicalxpress.com · 1 view
    FDA clears Sunharbo, first factor XIa inhibitor to prevent second strokes
  • Health & science 5 hours ago · medicalxpress.com · 1 view
    FDA Approves Rybrevant Faspro for Advanced Head and Neck Cancer
Catcher tip line

Caught a story we missed?

Log in and send it in. If it checks out, it runs with your name on it and you earn stock tokens. The bigger the story, the bigger the reward.

Submit a story
The newsletter

Get the paper in your inbox.

A short digest of the biggest news, plus optional breaking alerts. Free, no account needed.